Study of HRS-1167 with abiraterone for metastatic prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new combination of two study drugs (HRS-1167 and abiraterone with prednisone) for men with prostate cancer that has spread beyond the prostate. The goal is to see if the combination works better than current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man, 18 years or older
- You have been diagnosed with prostate cancer that has spread to other parts of the body (metastatic)
- You are in good general health (able to care for yourself and do light activities)
- You have not had other cancer in the last 3 years (except for certain skin or thyroid cancers that were cured)
- You are not currently taking strong steroids or immunosuppressants for other conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of three new drugs (SHR3680, HS-20093, and SHR2554) can help slow or stop prostate cancer growth. It is for men who are already on hormone therapy and whose PSA level is still rising.
This trial tests a new tablet called HRS-5041 combined with other anti-cancer treatments for men with advanced prostate cancer that has not responded to previous therapies. It aims to see how well the combination works and if it is safe.
This trial is testing an investigational drug, HRS-7525, for men with advanced prostate cancer that has spread to other parts of the body. The goal is to see if the drug is safe and effective.
This trial studies how well abiraterone (a hormone-blocking medicine) plus prednisone (a steroid) works in people with metastatic, hormone-sensitive prostate cancer. It also looks at whether results differ by race/ethnicity and other health factors.
This study tests different ways of giving hormone therapy to find the right dose for men with prostate cancer that has spread. It aims to help manage the disease while limiting side effects.
This trial tests a new drug called SHR-4394 combined with standard hormone therapy for men with prostate cancer that has spread to other parts of the body. The goal is to see if this combination can help control the cancer.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.